JPY 75.0
(-1.32%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - JPY | -100.0% |
2022 | 40.5 Million JPY | 3581.82% |
2021 | 1.1 Million JPY | -99.68% |
2020 | 342 Million JPY | -46.89% |
2019 | 644 Million JPY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - JPY | 0.0% |
2024 Q2 | - JPY | 0.0% |
2023 Q1 | - JPY | 0.0% |
2023 Q4 | - JPY | 0.0% |
2023 Q3 | - JPY | 0.0% |
2023 FY | - JPY | -100.0% |
2023 Q2 | - JPY | 0.0% |
2022 Q3 | - JPY | 0.0% |
2022 FY | 40.5 Million JPY | 3581.82% |
2022 Q4 | - JPY | 0.0% |
2021 FY | 1.1 Million JPY | -99.68% |
2020 FY | 342 Million JPY | -46.89% |
2019 FY | 644 Million JPY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 100.0% |
Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 100.0% |
Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 100.0% |
Shionogi & Co., Ltd. | 435.08 Billion JPY | 100.0% |
Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | 100.0% |
Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 100.0% |
Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 100.0% |
Eisai Co., Ltd. | 741.75 Billion JPY | 100.0% |
Morishita Jintan Co., Ltd. | 12.4 Billion JPY | 100.0% |
Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 100.0% |
Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 100.0% |
Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 100.0% |
Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 100.0% |
Tsumura & Co. | 150.84 Billion JPY | 100.0% |
Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 100.0% |
Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 100.0% |
Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 100.0% |
Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 100.0% |
Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 100.0% |
KYORIN Holdings, Inc. | 119.53 Billion JPY | 100.0% |
Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | 100.0% |
Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 100.0% |
SymBio Pharmaceuticals Limited | 5.58 Billion JPY | 100.0% |
MedRx Co., Ltd | 26 Million JPY | 100.0% |
Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | 100.0% |
Solasia Pharma K.K. | 617 Million JPY | 100.0% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 100.0% |
Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 100.0% |
Cyfuse Biomedical K.K. | 61.11 Million JPY | 100.0% |
Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 100.0% |
Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 100.0% |